# HIBADH

## Overview
The HIBADH gene encodes the enzyme 3-hydroxyisobutyrate dehydrogenase, which is a crucial component of the mitochondrial metabolic pathway involved in the catabolism of the branched-chain amino acid valine. This enzyme is responsible for converting 3-hydroxyisobutyrate to methylmalonate semialdehyde, a key step in valine degradation that contributes to energy production and amino acid balance within cells (Zheng2014HIBADH). As a dehydrogenase, HIBADH plays a significant role in preventing the accumulation of toxic metabolic intermediates, thereby maintaining cellular homeostasis (Meyer20213‐Hydroxyisobutyrate). The gene is expressed in various tissues and is implicated in broader metabolic and regulatory networks, including those associated with depression (Xu2024Preliminary). Mutations in HIBADH can lead to metabolic disorders such as 3-hydroxyisobutyric aciduria, highlighting its clinical significance (Wanders2015Branched).

## Function
3-hydroxyisobutyrate dehydrogenase (HIBADH) is an enzyme that plays a critical role in the catabolism of the branched-chain amino acid valine. In healthy human cells, HIBADH catalyzes the conversion of 3-hydroxyisobutyrate (3HiB) to methylmalonate semialdehyde, a key step in the valine degradation pathway (Zheng2014HIBADH). This process occurs in the mitochondria and is essential for maintaining amino acid balance and energy production within the cell (Zheng2014HIBADH).

The enzyme's activity prevents the accumulation of potentially toxic intermediates, such as 3HiB, which can lead to metabolic disorders if not properly managed (Meyer20213‐Hydroxyisobutyrate). In the context of valine metabolism, HIBADH's function is crucial for the conversion of valine into succinyl-CoA, a component of the citrate cycle, thereby contributing to the cycle's anaplerotic function (Zheng2014HIBADH).

HIBADH is expressed in various tissues, including fibroblasts, where it facilitates the metabolism of 3-hydroxyisobutyric acid, underscoring its role in cellular metabolic processes (Wanders2015Branched). The enzyme's activity is vital for normal cellular function and energy homeostasis, highlighting its importance in human physiology.

## Clinical Significance
Mutations in the HIBADH gene, which encodes the enzyme 3-hydroxyisobutyrate dehydrogenase, are associated with a metabolic disorder known as 3-hydroxyisobutyric aciduria. This condition is characterized by the accumulation of 3-hydroxyisobutyric acid in the urine due to a deficiency in the enzyme's activity, leading to a range of clinical symptoms. Patients with HIBADH deficiency may experience mild symptoms such as vomiting and normal cognitive development, or more severe manifestations including motor delays, mental retardation, and early death. Dysmorphic features such as a small triangular face, low-set ears, and microcephaly may also be present (Wanders2015Branched).

In some cases, treatment with a low-protein diet and carnitine supplementation has been shown to reduce the levels of abnormal metabolites, although it does not completely normalize them (Wanders2015Branched). A specific mutation, c.582dupC p. (Asn195Glnfs*25), has been identified, leading to a frameshift and premature stop-codon, resulting in nonsense-mediated mRNA decay and a complete loss of enzyme function (Meyer20213‐Hydroxyisobutyrate). This mutation causes elevated excretion of 3-hydroxyisobutyric acid and is associated with developmental delays and cognitive impairments (Meyer20213‐Hydroxyisobutyrate).

## Interactions
HIBADH, or 3-hydroxyisobutyrate dehydrogenase, is involved in the metabolic pathway of branched-chain amino acids (BCAAs), specifically in the catabolism of valine. This enzyme is noted for its role in encoding the small molecule 3-hydroxyisobutyrate (3-HIB), which is an intermediate in the valine degradation pathway. HIBADH has been identified as physically interacting with several other proteins, including PSBM4, SLC25A12, and GMPPB, through protein-protein interactions (Xu2024Preliminary). These interactions are part of a broader local gene network (LGN) related to depression, constructed to explore the regulatory and metabolic pathways associated with this condition. The study suggests that these interactions may play a role in the regulatory aspects of depression, highlighting the potential of HIBADH in influencing depression-related pathways through its involvement in metabolic and regulatory networks (Xu2024Preliminary). The STRING database was utilized to map these interactions, providing a framework for understanding the complex relationships between HIBADH and other proteins within the context of depression and metabolic regulation (Xu2024Preliminary).


## References


[1. (Meyer20213‐Hydroxyisobutyrate) Melanie Meyer, Jana C. Hollenbeck, Janine Reunert, Anja Seelhöfer, Stephan Rust, Manfred Fobker, Saskia Biskup, Ulrike Och, Mechthild Linden, Jörn Oliver Sass, and Thorsten Marquardt. <scp>3‐hydroxyisobutyrate</scp> dehydrogenase (hibadh) deficiency—a novel disorder of valine metabolism. Journal of Inherited Metabolic Disease, 44(6):1323–1329, July 2021. URL: http://dx.doi.org/10.1002/jimd.12410, doi:10.1002/jimd.12410. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jimd.12410)

[2. (Zheng2014HIBADH) Tie-long Zheng, Ping-an Wang, Dian-li Wang, Cheng-fu Sun, Yuan Hong, Qi Wang, and Jun Cheng. Hibadh plays an important role in the course of liver cell necrosis. Infection International, 3(2):64–70, June 2014. URL: http://dx.doi.org/10.1515/ii-2017-0077, doi:10.1515/ii-2017-0077. This article has 0 citations.](https://doi.org/10.1515/ii-2017-0077)

[3. (Xu2024Preliminary) Jiacheng Xu. Preliminary evaluation of the value of small molecular nutrients in depression-specific local metabolic network in preventing and treating depression. BIO Web of Conferences, 124:01014, 2024. URL: http://dx.doi.org/10.1051/bioconf/202412401014, doi:10.1051/bioconf/202412401014. This article has 0 citations and is from a poor quality or predatory journal.](https://doi.org/10.1051/bioconf/202412401014)

[4. (Wanders2015Branched) Ronald J. A. Wanders, Marinus Duran, and Ference Loupatty. Branched Chain Amino Acid Oxidation Disorders, pages 129–143. Springer New York, 2015. URL: http://dx.doi.org/10.1007/978-1-4939-1923-9_11, doi:10.1007/978-1-4939-1923-9_11. This article has 0 citations.](https://doi.org/10.1007/978-1-4939-1923-9_11)